Scientists Marched To Protect NIH Grants, But Where Was Pharma?
Executive Summary
Funding from the US National Institutes of Health is a vital source for biomedical research and pharmaceutical pipelines in turn – but biopharma companies have been largely silent on the matter.
You may also be interested in...
Biotech Execs Promote Biomedical R&D At White House Meeting
At meeting led by NIH Director Collins, participants talked about importance of biomedical research and need for partnerships between industry, government and academia.
Promise Of US Tax Reform Simmers, But On The Backburner
The pharmaceutical industry will have to keep waiting for US tax reform, most likely until at least the end of 2017. President Trump plans to revisit health care reform first to generate the savings needed for "phenomenal" tax reform.
20 Drugs That Got Their Start, In Part, With US Public Funding
The Trump Administration’s budget proposal aims to slash NIH funding that's critical to drug discovery and early research. Here’s a look at 20 of the 213 FDA-approved drugs that benefited from public grants, including IO pioneer Yervoy.